Skip to main content
. Author manuscript; available in PMC: 2015 Jan 17.
Published in final edited form as: J Neurooncol. 2014 May 7;119(1):135–140. doi: 10.1007/s11060-014-1460-z

Table 2.

Treatment regimens of early and delayed BEV groups

Regimen Early BEV (N) Delayed BEV (N)
BEV 23 32
BEV/irinotecan 58 77
BEV/temozolomide 13 7
BEV/carboplatin 6 5
BEV/carmustine 1 1
BEV/lomustine 1 0
BEV/cis-retinoic acid 4 1
BEV/capecitabine 1 1
BEV/erlotinib 2 0
BEV/gemcitabine 0 1
BEV/etoposide 0 1
BEV/temsirolimus 0 1
BEV/tamoxifen 0 1
BEV/temozolomide/6-thioguanine 0 1
BEV/carboplatin/etoposide 1 0
BEV/irinotecan/cis-retinoic acid 2 0
BEV/imatinib/hydroxyurea 0 1
BEV/procarbazine/lomustine/6-Thioguanine/hydroxyurea 0 3
Total 112 133